Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases
Open Access
- 22 March 2007
- journal article
- review article
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 75 (3) , 499-514
- https://doi.org/10.1007/s00253-007-0912-1
Abstract
Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications.Keywords
This publication has 106 references indexed in Scilit:
- Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitorActa Crystallographica Section F Structural Biology and Crystallization Communications, 2007
- An active site tyrosine residue is essential for amidohydrolase but not for esterase activity of a class 2 histone deacetylase-like bacterial enzymeBiochemical Journal, 2007
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007
- Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitorProceedings of the National Academy of Sciences, 2006
- Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01British Journal of Cancer, 2006
- A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibitionNature Genetics, 2006
- Novel Three-Pronged Strategy to Enhance Cancer Cell Killing in Glioblastoma Cell Lines: Histone Deacetylase Inhibitor, Chemotherapy, and Oncolytic Adenovirus dl520Human Gene Therapy, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Members of the histone deacetylase superfamily differ in substrate specificity towards small synthetic substratesBiochemical and Biophysical Research Communications, 2004
- Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357Journal of Hepatology, 2004